デフォルト表紙
市場調査レポート
商品コード
1474920

米国の前臨床CROの市場規模、シェア、動向分析レポート:サービス別、モデルタイプ別、技術別、最終用途別、州別、セグメント予測、2024年-2030年

U.S. Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis & DMPK Studies, Toxicology Testing), By Model Type, By Technology, By End-use, By State, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 80 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
米国の前臨床CROの市場規模、シェア、動向分析レポート:サービス別、モデルタイプ別、技術別、最終用途別、州別、セグメント予測、2024年-2030年
出版日: 2024年04月30日
発行: Grand View Research
ページ情報: 英文 80 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の前臨床CRO市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、米国の前臨床CRO市場規模は2030年までに59億米ドルに達し、2024年から2030年までのCAGRは7.1%で成長すると予測されています。

研究開発活動への支出が増加していることや、製薬会社がコスト削減に注力していることなどが市場成長の要因となっています。

初期段階・後期段階の医薬品開発プロセスに対する研究開発予算は大幅に増加しており、これが市場成長に寄与すると期待されています。また、バイオ医薬品の失敗率の上昇とそれに伴うコストが、バイオ製薬・ライフサイエンス企業が創薬・開発プロセスの初期段階により注力する原動力となっています。これは前臨床CRO市場の成長を促進すると思われます。

世界のアルツハイマー病患者の増加、最先端の遺伝子治療に対する需要、神経変性疾患の発生率、遺伝性疾患の有病率の高さなどは、先端治療の成長を促進する要因の一部です。大手・中小バイオテクノロジー企業の多くが、技術・製造能力の面でこの分野の技術革新を推進しており、市場拡大の商機を提供しています。

さらに、最近の新製品の承認は研究開発活動を加速させています。例えば、2023年12月、FDAは2つの画期的な治療法-CasgevyとLyfgenia-を承認しました。これらの治療法は、12歳以上の鎌状赤血球症患者に対する初の細胞ベースの遺伝子治療薬として、重要なマイルストーンとなった。

米国の前臨床CRO市場レポートハイライト:

  • 創薬研究は2023年に29.6%のシェアを占め、サービスセグメントを支配しました。これは、バイオテクノロジー・製薬企業において、創薬を加速しコストを削減するために研究をアウトソーシングする傾向が高まっているためです。
  • バイオ分析・DMPK研究分野は、バイオ分析研究におけるCROの広範な応用により、予測期間中に最も速いCAGRを示すと予想されます。
  • 個別化医療や先端治療薬に対する需要の増加、ライフサイエンス企業がコアコンピタンスに注力すること、アウトソーシングの増加傾向が予測期間中の市場成長を促進すると予想されます。
  • 2022年8月、WuXi STAは米国に190エーカーの医薬品製造キャンパスを新設すると発表しました。この施設は同社にとって2つ目の施設となり、米国・世界中の顧客のニーズに対応するための拡張能力と柔軟性を提供します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の前臨床CRO市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 米国の前臨床CRO市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国の前臨床CRO市場:サービスの推定・動向分析

  • サービスの市場シェア、2023年・2030年
  • セグメントダッシュボード
  • 米国の前臨床CRO市場、サービス別の展望
  • 2018年から2030年までの市場規模と予測・動向分析

第5章 米国の前臨床CRO市場:モデルタイプの推定・動向分析

  • モデルタイプの市場シェア、2023年・2030年
  • セグメントダッシュボード
  • 米国の前臨床CRO市場、モデルタイプ別の展望
  • 2018年から2030年までの市場規模と予測・動向分析

第6章 米国の前臨床CRO市場:技術の推定・動向分析

  • 技術の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 米国の前臨床CRO市場、技術別の展望
  • 2018年から2030年までの市場規模と予測・動向分析

第7章 米国の前臨床CRO市場:最終用途の推定・動向分析

  • 最終用途の市場シェア、2023年・2030年
  • セグメントダッシュボード
  • 米国の前臨床CRO市場、最終用途別の展望
  • 2018年から2030年までの市場規模と予測・動向分析

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
  • 企業プロファイル
    • Laboratory Corporation of America
    • Lonza
    • WuXi AppTec, Inc.
    • Eurofins Scientific SE
    • Intertek Group plc
    • Medpace Holdings, Inc.
    • Charles River Laboratories International, Inc.
    • SGA SA
    • Pharmaceutical Product Development, Inc.(Thermo Fisher Scientific, Inc.)
    • ICON plc
    • CROWN bioscience
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. preclinical CRO market, by services, 2018 - 2030 (USD Million)
  • Table 4 U.S. preclinical CRO market, by bioanalysis and DMK studies, 2018 - 2030 (USD Million)
  • Table 5 U.S. preclinical CRO market, by toxicology testing, 2018 - 2030 (USD Million)
  • Table 6 U.S. preclinical CRO market, by compound management, 2018 - 2030 (USD Million)
  • Table 7 U.S. preclinical CRO market, by chemistry, 2018 - 2030 (USD Million)
  • Table 8 U.S. preclinical CRO market, by safety pharmacology, 2018 - 2030 (USD Million)
  • Table 9 U.S. preclinical CRO market, by discovery research, 2018 - 2030 (USD Million)
  • Table 10 U.S. preclinical CRO market, by others, 2018 - 2030 (USD Million)
  • Table 11 U.S. preclinical CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 12 U.S. preclinical CRO market, by small animal models, 2018 - 2030 (USD Million)
  • Table 13 U.S. preclinical CRO market, by large animal models, 2018 - 2030 (USD Million)
  • Table 14 U.S. preclinical CRO market, by organoid models, 2018 - 2030 (USD Million)
  • Table 15 U.S. preclinical CRO market, by cell culture models, 2018 - 2030 (USD Million)
  • Table 16 U.S. preclinical CRO market, by others, 2018 - 2030 (USD Million)
  • Table 17 U.S. preclinical CRO market, by technology, 2018 - 2030 (USD Million)
  • Table 18 U.S. preclinical CRO market, by in vivo studies, 2018 - 2030 (USD Million)
  • Table 19 U.S. preclinical CRO market, by in vitro studies, 2018 - 2030 (USD Million)
  • Table 20 U.S. preclinical CRO market, by ex vivo studies, 2018 - 2030 (USD Million)
  • Table 21 U.S. preclinical CRO market, by imaging technologies, 2018 - 2030 (USD Million)
  • Table 22 U.S. preclinical CRO market, by other technologies, 2018 - 2030 (USD Million)
  • Table 23 U.S. preclinical CRO market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 U.S. preclinical CRO market, by biopharmaceutical companies, 2018 - 2030 (USD Million)
  • Table 25 U.S. preclinical CRO market, by research and academic institutes, 2018 - 2030 (USD Million)
  • Table 26 U.S. preclinical CRO market, by medical device companies, 2018 - 2030 (USD Million)
  • Table 27 U.S. preclinical CRO market, by states, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. preclinical CRO market: market outlook
  • Fig. 9 U.S. preclinical CRO competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. preclinical CRO market driver impact
  • Fig. 14 U.S. preclinical CRO market restraint impact
  • Fig. 15 U.S. preclinical CRO market: Services movement analysis
  • Fig. 16 U.S. preclinical CRO market: Services outlook and key takeaways
  • Fig. 17 Bioanalysis and DMPK studies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 In vitro ADME market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 In vivo PK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Toxicology testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 GLP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Non-GLP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Compound management market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Process R&D market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Custom synthesis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Medicinal chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Computation chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Safety pharmacology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Discovery research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Target identification & screening market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Target validation & functional informatics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Lead identification & candidate optimization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Preclinical development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Other associated workflow market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. preclinical CRO market: Model type movement analysis
  • Fig. 39 U.S. preclinical CRO market: Model type outlook and key takeaways
  • Fig. 40 Small animal models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Mice model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Rats model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Rabbits model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Other model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Large animal models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Pigs model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Other model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Organoid models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Cell culture models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. preclinical CRO market: Technology movement analysis
  • Fig. 52 U.S. preclinical CRO market: Technology outlook and key takeaways
  • Fig. 53 In vivo studies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 In vitro studies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Ex vivo market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Imaging technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Ultrasound imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 MRI imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 CT imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Radionuclide imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Other imaging technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Other technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 U.S. preclinical CRO market: End-use movement analysis
  • Fig. 64 U.S. preclinical CRO market: End-use outlook and key takeaways
  • Fig. 65 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-257-3

U.S. Preclinical CRO Market Growth & Trends:

The U.S. preclinical CRO market size is anticipated to reach USD 5.9 billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as the increasing expenditure on R&D activities and the focus of pharmaceutical companies on cost reduction are driving the market growth.

There has been a significant increase in the R&D budget for early-stage and late-stage drug development processes, which is expected to contribute to market growth. The rising biopharmaceutical failure rates and the costs they entail have also driven the biopharmaceutical & life sciences companies to focus more on the early stage of the drug discovery and development process. This is likely to propel the growth of the market for preclinical CRO.

The increasing cases of Alzheimer's disease globally, demand for cutting-edge gene therapies, incidence of neurodegenerative diseases, and high prevalence of genetic disorders are some of the factors promoting the growth of advanced therapies. A substantial number of major & small biotechnology companies are driving innovation in this field in terms of technology & manufacturing capabilities, thereby offering commercial opportunities for market expansion.

Furthermore, the recent approval of new products has accelerated R&D activities. For instance, in December 2023, the FDA approved two groundbreaking treatments-Casgevy and Lyfgenia. These treatments mark a significant milestone as the first cell-based gene therapies suggested for the treatment of sickle cell disease in patients aged 12 and older.

U.S. Preclinical CRO Market Report Highlights:

  • Discovery research dominated the service segment with 29.6% share in 2023, owing to the rising trend of outsourcing research in the biotechnology and pharmaceutical companies to accelerate drug discovery and reduce cost.
  • The bioanalysis and DMPK studies segment is expected to witness the fastest CAGR over the forecast period, owing to widescale applications of CROs in bioanalysis studies.
  • Increasing demand for personalized medicine and advanced therapeutics, life science companies focusing on their core competencies, and the increasing trend of outsourcing are expected to drive the market growth over the forecast period.
  • In August 2022, WuXi STA announced its new 190-acre pharmaceutical manufacturing campus in the U.S. This site would be its second facility, offering expanded capacity and flexibility to meet customers' needs in the U.S. and across the globe.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Services
    • 1.2.2. Model Type
    • 1.2.3. Technology
    • 1.2.4. End-use
    • 1.2.5. States
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Services outlook
    • 2.2.2. Model Type outlook
    • 2.2.3. Technology outlook
    • 2.2.4. End-use outlook
    • 2.2.5. States outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Preclinical CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising outsourcing trend
      • 3.2.1.2. Increasing focus of life science companies on their core competencies
      • 3.2.1.3. Increasing demand of personalized medicine and advanced therapeutics
      • 3.2.1.4. Increasing pharmaceutical R&D investments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Monitoring issues and lack of standardization
      • 3.2.2.2. Managing relationships
  • 3.3. U.S. Preclinical CRO Market Analysis Tools
    • 3.3.1. Industry analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Preclinical CRO Market: Services Estimates & Trend Analysis

  • 4.1. Services Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Preclinical CRO Market by Services Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Bioanalysis and DMPK studies
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. In vitro ADME
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. In-vivo PK
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Toxicology testing
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. GLP
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Non-GLP
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Compound management
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.2. Process R&D
      • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.3. Custom synthesis
      • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.4. Others
      • 4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Chemistry
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.4.2. Medicinal chemistry
      • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.4.3. Computation chemistry
      • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Safety pharmacology
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Discovery research
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.2. Target identification & screening
      • 4.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.3. Target validation & functional informatics
      • 4.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.4. Lead identification & candidate optimization
      • 4.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.5. Preclinical development
      • 4.4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.6. Other associated workflow
      • 4.4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Preclinical CRO Market: Model Type Estimates & Trend Analysis

  • 5.1. Model Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Preclinical CRO Market by Model Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Small animal models
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Mice
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Rats
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Rabbits
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
      • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Large animal models
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Pig
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Others
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Organoid models
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Cell culture models
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Preclinical CRO Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Preclinical CRO Market by Technology Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. In vivo studies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. In vitro studies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Ex vivo studies
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Imaging technologies
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.2. Ultrasound imaging
      • 6.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.3. MRI imaging
      • 6.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.4. CT imaging
      • 6.4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.5. Radionuclide imaging
      • 6.4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.6. Other imaging technologies
      • 6.4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Other technologies
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Preclinical CRO Market: End-use Estimates & Trend Analysis

  • 7.1. End-use Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Preclinical CRO Market by End-use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Biopharmaceutical companies
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Research and academic institutes
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Medical device companies
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Laboratory Corporation of America
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Lonza
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. WuXi AppTec, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Eurofins Scientific SE
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Intertek Group plc
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Medpace Holdings, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Charles River Laboratories International, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. SGA SA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.)
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. ICON plc
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. CROWN bioscience
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives